- Home
- NAGE vs BRBI Comparison
NAGE vs BRBI Comparison
Compare NAGE & BRBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAGE | BRBI |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | Brazil |
| Employees | 117 | 188 |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.2M | 293.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NAGE | BRBI |
|---|---|---|
| Price | $3.49 | $11.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 719.7K | 1.2K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 5.03% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.51 | N/A |
| Revenue Next Year | $14.58 | $17.24 |
| P/E Ratio | $21.29 | ★ $11.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $10.90 |
| 52 Week High | $11.29 | $67.01 |
Technical Indicators
Market Signals| Indicator | NAGE | BRBI |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 41.33 |
| Support Level | $3.35 | $10.90 |
| Resistance Level | $3.60 | $15.06 |
| Average True Range (ATR) | 0.16 | 0.20 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 47.56 | 20.15 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About BRBI BRBI BR Partners S.A. ADSs
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered. However, the company divides it's operations into the following business lines: (1) investment banking and capital markets, (2) treasury sales & structuring, (3) investments and wealth management and (4) capital remuneration.